Patient, disease, and transplantation characteristics
| . | Allele-level HLA match . | ||||||
|---|---|---|---|---|---|---|---|
| . | Matched . | 1-allele mismatch . | 2-allele mismatch . | 3-allele mismatch . | 4-allele mismatch . | 5-allele mismatch . | P value . |
| Number | 117 | 230 | 413 | 466 | 256 | 86 | |
| Gender, male | 67 (57%) | 116 (50%) | 223 (54%) | 272 (58%) | 134 (52%) | 49 (57%) | .33 |
| Age at transplantation | <.001 | ||||||
| ≤16 years | 101 (86%) | 178 (77%) | 322 (78%) | 313 (67%) | 152 (59%) | 53 (62%) | |
| >16 years | 16 (14%) | 52 (23%) | 91 (22%) | 153 (33%) | 104 (41%) | 33 (38%) | |
| Recipient cytomegalovirus seropositivity | .56 | ||||||
| Positive | 61 (52%) | 123 (53%) | 196 (47%) | 248 (53%) | 125 (49%) | 47 (55%) | |
| Negative | 53 (45%) | 97 (42%) | 202 (49%) | 206 (44%) | 124 (48%) | 34 (40%) | |
| Not reported | 3 (3%) | 10 (4%) | 15 (4%) | 12 (3%) | 7 (3%) | 5 (5%) | |
| Disease | .77 | ||||||
| Acute myeloid leukemia | 47 (40%) | 86 (37%) | 141 (34%) | 172 (37%) | 113 (44%) | 32 (37%) | |
| Acute lymphoblastic leukemia | 60 (51%) | 117 (51%) | 233 (56%) | 256 (55%) | 110 (43%) | 44 (51%) | |
| Myelodysplastic syndrome | 10 (9%) | 27 (12%) | 39 (9%) | 38 (8%) | 33 (13%) | 10 (12%) | |
| Disease status | .52 | ||||||
| First complete remission | 50 (43%) | 75 (33%) | 160 (39%) | 162 (35%) | 77 (30%) | 27 (31%) | |
| Second complete remission | 47 (40%) | 95 (41%) | 158 (38%) | 217 (47%) | 97 (38%) | 36 (42%) | |
| Relapse/RAEB | 20 (17%) | 59 (26%) | 95 (23%) | 86 (18%) | 81 (32%) | 23 (27%) | |
| Not reported | __ | 1 (<1%) | __ | 1 (<1%) | 1 (<1%) | __ | |
| Conditioning regimen | .88 | ||||||
| TBI containing regimen | 60 (51%) | 122 (53%) | 226 (55%) | 260 (56%) | 132 (52%) | 49 (62%) | |
| Non-TBI containing regimen | 57 (49%) | 108 (47%) | 187 (45%) | 206 (44%) | 124 (48%) | 37 (38%) | |
| In vivo T-cell depletion | .14 | ||||||
| Yes | 87 (74%) | 165 (72% | 290 (70%) | 344 (74%) | 201 (79%) | 69 (80%) | |
| None | 28 (24%) | 52 (23%) | 106 (26%) | 111 (24%) | 47 (18%) | 14 (16%) | |
| Not reported | 2 (2%) | 13 (6%) | 17 (4%) | 11 (2%) | 8 (3%) | 3 (3%) | |
| Total nucleated cell dose, prefreeze | <.001 | ||||||
| <3 × 107/kg | 14 (12%) | 33 (14%) | 56 (14%) | 66 (14%) | 40 (16%) | 10 (12%) | |
| ≥3-5 × 107/kg | 18 (15%) | 52 (23%) | 99 (24%) | 156 (33%) | 99 (39%) | 31 (36%) | |
| >5 × 107/kg | 81 (69%) | 138 (60%) | 242 (59%) | 233 (50%) | 106 (41%) | 43 (50%) | |
| Not reported | 4 (4%) | 7 (3%) | 16 (4%) | 11 (2%) | 11 (4%) | 2 (2%) | |
| Transplant period | .04 | ||||||
| 2000-2004 | 28 (24%) | 74 (32%) | 136 (33%) | 128 (27%) | 91 (36%) | 34 (40%) | |
| 2005-2010 | 89 (76%) | 156 (68%) | 277 (67%) | 338 (73%) | 165 (64%) | 52 (60%) | |
| Follow-up, median (range), months | 37 (3-131) | 46 (5-132) | 46 (3-147) | 37 (3-127) | 45 (3-107) | 35 (3-122) | |
| . | Allele-level HLA match . | ||||||
|---|---|---|---|---|---|---|---|
| . | Matched . | 1-allele mismatch . | 2-allele mismatch . | 3-allele mismatch . | 4-allele mismatch . | 5-allele mismatch . | P value . |
| Number | 117 | 230 | 413 | 466 | 256 | 86 | |
| Gender, male | 67 (57%) | 116 (50%) | 223 (54%) | 272 (58%) | 134 (52%) | 49 (57%) | .33 |
| Age at transplantation | <.001 | ||||||
| ≤16 years | 101 (86%) | 178 (77%) | 322 (78%) | 313 (67%) | 152 (59%) | 53 (62%) | |
| >16 years | 16 (14%) | 52 (23%) | 91 (22%) | 153 (33%) | 104 (41%) | 33 (38%) | |
| Recipient cytomegalovirus seropositivity | .56 | ||||||
| Positive | 61 (52%) | 123 (53%) | 196 (47%) | 248 (53%) | 125 (49%) | 47 (55%) | |
| Negative | 53 (45%) | 97 (42%) | 202 (49%) | 206 (44%) | 124 (48%) | 34 (40%) | |
| Not reported | 3 (3%) | 10 (4%) | 15 (4%) | 12 (3%) | 7 (3%) | 5 (5%) | |
| Disease | .77 | ||||||
| Acute myeloid leukemia | 47 (40%) | 86 (37%) | 141 (34%) | 172 (37%) | 113 (44%) | 32 (37%) | |
| Acute lymphoblastic leukemia | 60 (51%) | 117 (51%) | 233 (56%) | 256 (55%) | 110 (43%) | 44 (51%) | |
| Myelodysplastic syndrome | 10 (9%) | 27 (12%) | 39 (9%) | 38 (8%) | 33 (13%) | 10 (12%) | |
| Disease status | .52 | ||||||
| First complete remission | 50 (43%) | 75 (33%) | 160 (39%) | 162 (35%) | 77 (30%) | 27 (31%) | |
| Second complete remission | 47 (40%) | 95 (41%) | 158 (38%) | 217 (47%) | 97 (38%) | 36 (42%) | |
| Relapse/RAEB | 20 (17%) | 59 (26%) | 95 (23%) | 86 (18%) | 81 (32%) | 23 (27%) | |
| Not reported | __ | 1 (<1%) | __ | 1 (<1%) | 1 (<1%) | __ | |
| Conditioning regimen | .88 | ||||||
| TBI containing regimen | 60 (51%) | 122 (53%) | 226 (55%) | 260 (56%) | 132 (52%) | 49 (62%) | |
| Non-TBI containing regimen | 57 (49%) | 108 (47%) | 187 (45%) | 206 (44%) | 124 (48%) | 37 (38%) | |
| In vivo T-cell depletion | .14 | ||||||
| Yes | 87 (74%) | 165 (72% | 290 (70%) | 344 (74%) | 201 (79%) | 69 (80%) | |
| None | 28 (24%) | 52 (23%) | 106 (26%) | 111 (24%) | 47 (18%) | 14 (16%) | |
| Not reported | 2 (2%) | 13 (6%) | 17 (4%) | 11 (2%) | 8 (3%) | 3 (3%) | |
| Total nucleated cell dose, prefreeze | <.001 | ||||||
| <3 × 107/kg | 14 (12%) | 33 (14%) | 56 (14%) | 66 (14%) | 40 (16%) | 10 (12%) | |
| ≥3-5 × 107/kg | 18 (15%) | 52 (23%) | 99 (24%) | 156 (33%) | 99 (39%) | 31 (36%) | |
| >5 × 107/kg | 81 (69%) | 138 (60%) | 242 (59%) | 233 (50%) | 106 (41%) | 43 (50%) | |
| Not reported | 4 (4%) | 7 (3%) | 16 (4%) | 11 (2%) | 11 (4%) | 2 (2%) | |
| Transplant period | .04 | ||||||
| 2000-2004 | 28 (24%) | 74 (32%) | 136 (33%) | 128 (27%) | 91 (36%) | 34 (40%) | |
| 2005-2010 | 89 (76%) | 156 (68%) | 277 (67%) | 338 (73%) | 165 (64%) | 52 (60%) | |
| Follow-up, median (range), months | 37 (3-131) | 46 (5-132) | 46 (3-147) | 37 (3-127) | 45 (3-107) | 35 (3-122) | |
TBI dose ranged from 800-1440 cGy; 75% received 1200 cGy or 1320 cGy; n = 4 received 800 cGy and n = 1 received 900 cGy. In vivo T-cell depletion: 1156 transplant regimens included in vivo T-cell depletion. Of these, 1146 received ATG (548 rabbit ATG, 284, equine ATG, and information was not available for 314); 10 patients received alemtuzumab.
ATG, anti-thymocyte globulin; RAEB, refractory anemia with excess blast; TBI, total body irradiation.